-
公开(公告)号:US20090155187A1
公开(公告)日:2009-06-18
申请号:US12353646
申请日:2009-01-14
IPC分类号: A61K9/12 , A61K31/501
CPC分类号: A61K31/501 , C07D237/14
摘要: To provide an intimal hyperplasia inhibitor useful for prevention of restenosis after percutaneous transluminal coronary angioplasty (PTCA) or vascular stent placement or treatment of its progress.An intimal hyperplasia inhibitor containing a 3(2H)-pyridazinone compound represented by the formula (I): [wherein each of R1, R2 and R3 is independently a hydrogen atom or a C1-6 alkyl group, X is a halogen atom, cyano or a hydrogen atom, Y is a halogen atom, trifluoromethyl or a hydrogen atom, and A is a C1-8 alkylene which may be substituted with a hydroxyl group] or a pharmacologically acceptable salt thereof.
摘要翻译: 提供内皮增生抑制剂,可用于预防经皮腔内冠状动脉成形术(PTCA)或血管支架置入或治疗其进展后的再狭窄。 含有由式(I)表示的3(2H) - 哒嗪酮化合物的内膜增生抑制剂:其中R 1,R 2和R 3各自独立地为氢原子或C 1-6烷基,X为卤素原子,氰基 或氢原子,Y为卤素原子,三氟甲基或氢原子,A为可被羟基取代的C 1-8亚烷基]或其药理学上可接受的盐。
-
公开(公告)号:US20070161642A1
公开(公告)日:2007-07-12
申请号:US10585949
申请日:2005-02-02
IPC分类号: A61K31/501 , C07D403/02
CPC分类号: A61K31/501 , C07D237/14
摘要: An intimal hyperplasia inhibitor containing a 3(2H)-pyridazinone compound represented by the formula (I): [wherein each of R1, R2 and R3 is independently a hydrogen atom or a C1-6 alkyl group, X is a halogen atom, cyano or a hydrogen atom, Y is a halogen atom, trifluoromethyl or a hydrogen atom, and A is a C1-8 alkylene which may be substituted with a hydroxyl group] or a pharmacologically acceptable salt thereof.
摘要翻译: 含有由式(I)表示的3(2H) - 哒嗪酮化合物的内膜增生抑制剂:其中R 1,R 2,R 3和R 3 独立地是氢原子或C 1-6烷基,X是卤素原子,氰基或氢原子,Y是卤素原子,三氟甲基或氢原子,和 A是可以被羟基取代的C 1-8烷基亚烷基]或其药理学上可接受的盐。
-
公开(公告)号:US5508403A
公开(公告)日:1996-04-16
申请号:US463511
申请日:1995-06-05
申请人: Shin-ichi Akiyama , Ryozo Sakoda , Kiyotomo Seto , Norimasa Shudo
发明人: Shin-ichi Akiyama , Ryozo Sakoda , Kiyotomo Seto , Norimasa Shudo
IPC分类号: A61K31/675 , A61K31/44 , A61K31/445 , A61K31/495 , A61K31/535 , A61K31/66 , A61K31/665 , A61P35/00 , A61P43/00 , C07D213/80 , C07F9/58 , C07F9/59 , C07F9/6558 , C07F9/6571 , C07F9/6574
CPC分类号: A61K31/44 , A61K31/445 , A61K31/495 , A61K31/535 , A61K31/66 , A61K31/665 , A61K31/675 , C07F9/587 , C07F9/597 , C07F9/657181
摘要: An agent for enhancing the drug effects of an antitumor drug, which comprises a compound of the formula I: ##STR1## or a pharmaceutically acceptable salt of the compound.
摘要翻译: 一种用于增强抗肿瘤药物的药物作用的药剂,其包含式I化合物或其药学上可接受的盐。
-
公开(公告)号:US5968967A
公开(公告)日:1999-10-19
申请号:US51085
申请日:1998-04-13
IPC分类号: A61K31/415 , A61K31/44 , A61K31/4427 , A61K31/445 , A61K31/47 , A61K31/495 , A61P7/02 , A61P9/08 , A61P9/10 , C07D231/12 , C07D231/14 , C07D231/20 , C07D231/22 , C07D401/04 , C07D401/06 , C07D401/14 , C07D403/04 , C07D403/06
CPC分类号: C07D231/12 , C07D231/14 , C07D231/20 , C07D231/22 , C07D401/04 , C07D401/06 , C07D401/14 , C07D403/04
摘要: A pyrazolone derivative represented by general formula (I) or a salt thereof: ##STR1## [wherein one of X.sup.1 and X.sup.2 is ##STR2## (wherein A is a cyano group, a cyano C.sub.1-4 alkyl group, an amino group, an amino C.sub.1-4 alkyl group, an amidino group or a guanidino group, R.sup.1 and R.sup.2 are independently hydrogen atoms, halogen atoms, C.sub.1-6 alkyl groups or the like) or the like],the other of X.sup.1 and X.sup.2 is a C.sub.1-6 alkyl group, a C.sub.3-6 alkenyl group, an aryl C.sub.1-4 alkyl group or an aryl group,one of Y.sup.1 and Y.sup.2 is ##STR3## (wherein Q is an oxygen atom or a sulfur atom, Z.sup.1 is an oxygen atom, a --NR.sup.7 -- group or a --CHR.sup.7 -- group, Z.sup.2 is a cyclic C.sub.3-7 alkylene group, a C.sub.1-3 alkylene group, a --CH.sub.2 CO-- group or --CH.sub.2 CH.sub.2 CO-- group, Z.sup.3 is an oxygen atom, a sulfur atom, a sulfinyl group, a sulfonyl group or the like, Z.sup.4 is a C.sub.1-3 alkylene group, and Z.sup.5 is a carboxyl group or the like, andthe other of Y.sup.1 and Y.sup.2 is a D-E- group [wherein E is a bond, a C.sub.1-4 alkylene group or a phenylene group, and D is a hydrogen atom, a C.sub.1-6 alkyl group or the like which has an inhibitory action on platelet aggregation and is useful as a preventive or therapeutic agent for various thrombotic diseases.
摘要翻译: PCT No.PCT / JP96 / 02944 Sec。 371日期:1998年4月13日 102(e)1998年4月13日PCT PCT 1996年10月11日PCT公布。 第WO97 / 13757号公报 日本1997年4月17日由通式(I)表示的吡唑啉酮衍生物或其盐:其中X1和X2之一为(其中A为氰基,氰基C1-4烷基,氨基,氨基 C 1-4烷基,脒基或胍基,R 1和R 2独立地为氢原子,卤素原子,C 1-6烷基等),X 1和X 2中的另一个为C 1-6 烷基,C 3-6烯基,芳基C 1-4烷基或芳基,Y1和Y2之一为(其中Q为氧原子或硫原子,Z1为氧原子,-NR7- 基团或-CHR7-基团,Z2为环状C3-7亚烷基,C1-3亚烷基,-CH2CO-基或-CH2CH2CO-基,Z3为氧原子,硫原子,亚磺酰基, 磺酰基等,Z4为C1-3亚烷基,Z5为羧基等,Y1和Y2中的另一个为DE-基[其中E为键,C1-4亚烷基 基团或亚苯基,D为氢原子,C1-6烷基 对血小板聚集具有抑制作用,可用作各种血栓性疾病的预防或治疗剂。
-
公开(公告)号:US08047962B2
公开(公告)日:2011-11-01
申请号:US12466134
申请日:2009-05-14
申请人: Norimasa Shudo , Suguru Ishida , Masaya Tamai , Akihiro Ueki
发明人: Norimasa Shudo , Suguru Ishida , Masaya Tamai , Akihiro Ueki
IPC分类号: F16H61/26
CPC分类号: F16H61/0021 , F16H61/0206 , F16H2061/0037 , Y10T477/6936 , Y10T477/69395
摘要: A hydraulic control device for an automatic transmission is provided. The hydraulic control device can sets up any gear from a plurality of gears by causing any one of a plurality of frictional engagement elements to selectively carry out an engagement operation. The hydraulic control device includes: a regulator valve that regulates base oil pressure of hydraulic oil supplied from an oil pressure source; a relief valve provided in a lubricating oil passage connected from the regulator valve; and a line pressure switching section that sets up line pressure to low pressure to reduce the amount of lubricating oil in a region in which engagement hydraulic oil pressure does not require high engagement hydraulic oil pressure depending upon an operation state of a vehicle, and sets up the line pressure to high pressure when a target value of the engagement hydraulic oil pressure exceeds predetermined pressure.
摘要翻译: 提供一种用于自动变速器的液压控制装置。 液压控制装置可以通过使多个摩擦接合元件中的任何一个选择性地执行接合操作来设置来自多个齿轮的任何齿轮。 液压控制装置包括:调节阀,其调节从油压源供给的液压油的基础油压; 设置在从调节阀连接的润滑油通路中的安全阀; 以及线路压力切换部,其将线路压力设定为低压,以减少接合液压油压力根据车辆的运行状态而不需要高接合液压油压的区域中的润滑油的量,并且设定 当接合液压油压力的目标值超过预定压力时,将压力提高到高压。
-
公开(公告)号:US5304550A
公开(公告)日:1994-04-19
申请号:US57902
申请日:1993-05-07
申请人: Shin-ichi Akiyama , Ryozo Sakoda , Kiyotomo Seto , Norimasa Shudo
发明人: Shin-ichi Akiyama , Ryozo Sakoda , Kiyotomo Seto , Norimasa Shudo
IPC分类号: A61K31/44 , A61K31/445 , A61K31/495 , A61K31/535 , A61K31/66 , A61K31/665 , A61K31/675 , C07F9/58 , C07F9/59 , C07F9/6571 , A61K31/55
CPC分类号: A61K31/44 , A61K31/445 , A61K31/495 , A61K31/535 , A61K31/66 , A61K31/665 , A61K31/675 , C07F9/587 , C07F9/597 , C07F9/657181
摘要: Compounds of the formula (I): ##STR1## in which the nitrogen-containing hetero ring portion is 1,4-dihydropyridine ring or a pyridine ring, R.sup.1 is only present when the nitrogen-containing hetero ring is a 1,4-dihydropyridine ring, and Z is a group of the formula (II): ##STR2## in which R.sup.4 and R.sup.5 may be the same or different and together may form one divalent group, are effective agents for enhancing the antitumor effect of antitumor drugs.
摘要翻译: 其中含氮杂环部分为1,4-二氢吡啶环或吡啶环的式(I)化合物:其中R 1仅在含氮杂环为1时存在, 并且Z是式(II)的基团:其中R 4和R 5可以相同或不同并且可以一起形成一个二价基团的式(II)的基团是用于增强抗肿瘤效果的有效药剂 的抗肿瘤药物。
-
公开(公告)号:US5130303A
公开(公告)日:1992-07-14
申请号:US729904
申请日:1991-07-15
申请人: Shin-ichi Akiyama , Ryozo Sakoda , Kiyotomo Seto , Norimasa Shudo
发明人: Shin-ichi Akiyama , Ryozo Sakoda , Kiyotomo Seto , Norimasa Shudo
IPC分类号: A61K31/44 , A61K31/445 , A61K31/495 , A61K31/535 , A61K31/66 , A61K31/665 , A61K31/675 , C07F9/58 , C07F9/59
CPC分类号: A61K31/44 , A61K31/445 , A61K31/495 , A61K31/535 , A61K31/66 , A61K31/665 , A61K31/675 , C07F9/587 , C07F9/597
摘要: Compounds of the formula (I): ##STR1## in which the nitrogen-containing hetero ring portion is a 1,4-dihydropyridine ring or a pyridine ring, R.sup.1 is only present when the nitrogen-containing hetero ring is a 1,4-dihydropyridine ring, and Z is either a CO.sub.2 R.sup.8 group or a group of the formula (II): ##STR2## in which R.sup.4 and R.sup.5 may be the same or different and together may form one divalent group, are effective agents for enhancing the antitumor effect or antitumor drugs.
-
-
-
-
-
-